Please ensure Javascript is enabled for purposes of website accessibility

Why BioNTech Stock Is Bouncing Back Today

By Keith Speights – Nov 8, 2021 at 12:09PM

Key Points

  • BioNTech stock sank last week after Pfizer announced great results for its COVID-19 pill.
  • Today's rebound appears to be the result of some investors thinking last week's sell-off went too far.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors appear to think last week's sell-off was overdone.

What happened

Shares of BioNTech (BNTX -1.62%) were jumping 8.4% as of 11:45 a.m. EST on Monday. The company didn't report any new developments today or over the weekend, though, that could have served as a catalyst. Instead, some investors appear to believe that BioNTech's sell-off last week went too far.

So what

The vaccine stock certainly hit a rough patch in recent days. BioNTech's shares fell 22% last week. Most of the decline came after Pfizer (PFE -0.63%) announced great results from a clinical study of its experimental COVID-19 pill.

A healthcare professional giving a shot to a person.

Image source: Getty Images.

Investors were concerned that the potential availability of safe and effective COVID pills could hurt sales of COVID vaccines, including Pfizer's and BioNTech's Comirnaty. Prior to Pfizer's good news on Friday, Merck (MRK -0.50%) and its partner Ridgeback Biotherapeutics announced positive results for their COVID pill, molnupiravir.

However, it's important to remember that (at least for now) governments are buying COVID vaccines. They're not likely to reduce their focus on vaccinations even with oral COVID therapies on the market. Pfizer's pill will probably have minimal impact on supply deals for Comirnaty in 2022 and 2023.

Now what

Over the longer term, COVID vaccine sales could be lower if the COVID pills are authorized for post-exposure prophylaxis. That could especially be the case if the U.S. government steps back from buying COVID vaccines. But there's a lot of uncertainty about how the dynamics of the COVID vaccine market will shake out beyond 2023 anyway. 

Keith Speights owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.